Albumin Bound Paclitaxel is an anticancer drug that belongs to the category of medicines known as microtubule inhibitors. It was approved by the U.S. FDA on the 7th of January 2005 to treat breast cancer.

Albumin Bound Paclitaxel is prescribed to treat ovarian cancer, breast cancer, non-small cell lung cancer and AIDS related Kaposi’s sarcoma.

The medicine will be administered to you by a healthcare professional in a hospital setting. It is usually administered as an intravenous infusion over 30-40 minutes on days 1, 8, and 15 of each 28-day cycle. The dose, route of administration, and frequency will be decided by your doctor based on your disease condition and other factors. 

The common side effects that are likely to occur while you are on the treatment with Albumin Bound Paclitaxel are tiredness, hair loss, muscle pain, bleeding, lip sores, and irritation at the injection site. Some serious side effects also include diarrhea, stomach pain, and hypersensitivity reactions. If you experience any allergic or unusual reactions after taking this medicine, report them to your doctor immediately.

It is not recommended to take an Albumin Bound Paclitaxel injection if you are allergic to any of its ingredients. This drug may be given alone or in combination with other anticancer medicines. This chemotherapy medication is contraindicated in patients with severe liver problems, uncontrolled infection, and low white blood cell or platelet count. Talk to your doctor if you have heart disorders before taking this medicine.

This drug is not recommended during pregnancy as it causes harm to the unborn baby. Tell your healthcare provider before beginning this treatment if you are pregnant or planning to have a baby. It is advised for both men and women to follow proper contraceptive methods during and for 3 months after the last dose of Albumin Bound Paclitaxel.

Albumin Bound Paclitaxel should be handled by the patient or the patient’s caregiver only. Women who are pregnant or might get pregnant should not handle damaged or broken medication without wearing gloves. If you forget to take this medication at your normal time, then take your usual dose whenever you remember, or if you forget to take this medication for the entire day, then take your usual dose the next day. However, do not double-dose yourself. Do not discontinue the usage of this medication without informing your doctor. Avoid driving and handling heavy machinery after taking this medication as it can affect the concentration and alertness.

1. Hospira UK Limited, Electronic medicines compendium (EMC), [ Revised on March 2020] [ Accessed on 22nd June 2021], https://www.medicines.org.uk/emc/files/pil.3891.pdf
2. Bristol-Myers Squibb Company, US Food and Drug Administration, [ Revised on April 2011] [ Accessed on 22nd June 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf
3. Spyridon Sideris et al; Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer; Molecular and Clinical Oncology; Published on 17/03/2016; Accessed on 26/05/2022; https://www.spandidos-publications.com/10.3892/mco.2016.821
4. Hiroko Machida et al; Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer; American Journal of Clinical Oncology; Published on 01/10/2020; Accessed on 26/05/2022; https://pubmed.ncbi.nlm.nih.gov/28763329
5. Dashan Ai MD et al; Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer A Randomized Clinical Trial; JAMA; Published on 21/02/2022; Accessed on 26/05/2022; https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789153
6. Linyan Zhu, Liqun Chen; Progress in research on paclitaxel and tumor immunotherapy; Cellular & Molecular Letters; Published on 13/06/2019; Accessed on 26/05/2022; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567594/
7. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Cytotoxic agents, 12th edition, 2011, 1707 - 1709.
8. KD Tripathi, Essentials of Medical Pharmacology, Anticancer drugs, 7th edition, 2013, 865.

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.